- Q4 2023 Amylyx Pharmaceuticals Inc Earnings Call TranscriptFeb 22, 2024$18.54 (+21.10%)Earnings
- Q3 2023 Amylyx Pharmaceuticals Inc Earnings Call TranscriptNov 09, 2023$12.26 (-31.89%)Earnings
- Amylyx Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Q2 2023 Amylyx Pharmaceuticals Inc Earnings Call TranscriptAug 10, 2023$21.17 (-1.49%)Earnings
- Amylyx Pharmaceuticals Inc To Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program TranscriptJul 26, 2023
- Amylyx Pharmaceuticals Inc at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Amylyx Pharmaceuticals Inc Annual Shareholders Meeting TranscriptJun 08, 2023
- Q1 2023 Amylyx Pharmaceuticals Inc Earnings Call TranscriptMay 11, 2023$28.82 (-0.41%)Earnings
- Amylyx Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) TranscriptApr 18, 2023
- Amylyx Pharmaceuticals Inc at Stifel CNS Days (Virtual) TranscriptMar 28, 2023
- Q4 2022 Amylyx Pharmaceuticals Inc Earnings Call TranscriptMar 13, 2023$31.17 (+1.66%)Earnings
- Amylyx Pharmaceuticals Inc at SVB Securities Global Biopharma Conference (Virtual) TranscriptFeb 14, 2023
- Amylyx Pharmaceuticals Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 29, 2022
- Q3 2022 Amylyx Pharmaceuticals Inc Earnings Call TranscriptNov 10, 2022$35.39 (+2.25%)Earnings
- Amylyx Pharmaceuticals Inc RELYVRIO™ FDA Approval Call TranscriptSep 30, 2022
- Amylyx Pharmaceuticals Inc Annual Shareholders Meeting TranscriptJun 09, 2022
Amylyx Pharmaceuticals Inc RELYVRIO™ FDA Approval Call Transcript
Good morning. My name is Rocco, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals RELYVRIO FDA approval Conference Call. (Operator Instructions)
Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Lindsey Allen, Head of Investor Relations and Communications. Please proceed.
Good morning, and thank you for joining us today to discuss the FDA approval of RELYVRIO, previously known as AMX0035 in the U.S. With me on the call are co-CEOs, Josh Cohen and Justin Klee; and Margaret Olinger, Chief Commercial Officer. Chief Financial Officer, Jim Frates, will be joining us for Q&A.
Before we begin, I would like to remind everyone that some of the statements that we make on this call and information presented in the slide deck include forward-looking statements that are based on our current plans and expectations, including with respect to RELYVRIO. Actual events and results could differ materially from
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)